RxDoctor Payments DataLook up a doctor →

Michele Jordan, MD

General Practice · Trussville, ALNPI 1982651436

Payments from drug & device makers

$11,367in general payments, 2019–2025

Across 639 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Otsuka America Pharmaceutical, Inc.$872
  • AstraZeneca$726
  • Amgen$711
  • Pfizer$633
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$11,23399%
  • Education$1341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,367 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama

Medicare billing

Part B allowed, 2024
$19,683
Medicare patients
56
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide130$155,680
OzempicSemaglutide72$85,036
JardianceEmpagliflozin41$52,586
FarxigaDapagliflozin Propanediol49$49,156
EliquisApixaban32$32,288
RybelsusSemaglutide21$25,675
JanuviaSitagliptin Phosphate25$22,416
TrulicityDulaglutide19$20,029
BelsomraSuvorexant43$18,392
XareltoRivaroxaban12$15,689
SynjardyEmpagliflozin/Metformin Hcl18$9,480
Pregabalin125$7,486
SymbicortBudesonide/Formoterol Fumarate13$5,230
VyvanseLisdexamfetamine Dimesylate12$4,686
Rosuvastatin Calcium164$3,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,131$175,708149 claims
Novo NordiskOzempic, Rybelsus$479$110,71193 claims
Boehringer IngelheimJardiance, Synjardy$484$62,06659 claims
AstraZenecaFarxiga, Symbicort$726$54,38662 claims
MerckJanuvia, Belsomra$107$40,80868 claims
PfizerEliquis$633$32,28832 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$263$4,68612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.

Other general practice in Trussville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →